Market research
PAL.AU Palla Pharma Limited
AU AUD Healthcare
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 48M
- P/E ratio
- Not available
- Analyst target
- 1.02
- Dividend yield
- 0.0%
- Beta
- 1.07
Profile
Instrument facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- ISIN
- AU0000049462
- Market cap
- 48M
- P/E ratio
- Not available
- Analyst target
- 1.02
- Dividend yield
- 0.0%
- Beta
- 1.07
About
About Palla Pharma Limited
Palla Pharma Limited, a vertically integrated pharmaceutical company, produces and distributes narcotic raw materials, active pharmaceutical ingredients, and finished dosage formulations for pharmaceutical markets in Australia and Norway. It also produces and distributes poppy seeds to culinary markets. The company was formerly known as TPI Enterprises Limited and changed its name to Palla Pharma Limited in June 2019. Palla Pharma Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Research context
Palla Pharma Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the PAL.AU discussion.
5 years, 6 months ago
Palla Pharma Limited is currently in a long term downtrend where the price is trading 36.1% below its 200 day moving average.
From a valuation standpoint, the stock is 57.3% cheaper than other stocks from the Consumer Defensive sector with a price to sales ratio of 2.9.
Palla Pharma Limited's total revenue sank by 64.4% to $10M since the same quarter in the previous year.
Its net income has dropped by 623.9% to $-26M since the same quarter in the previous year.
Finally, its free cash flow fell by 23.3% to $-5M since the same quarter in the previous year.
Based on the above factors, Palla Pharma Limited gets an overall score of 1/5.